Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Менопауза и климактерическое состояние у женщины

Список литературы

  1. J. Drewe, K. A. Bucher, and C. Zahner, “A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients,” pp. 1–29, 2015, doi: 10.1186/s40064-015-0808-y.
  2. P. F. Schnatz, A. Romegialli, J. Abrantes, K. Marakovits, D. Cunningham, and D. M. O’Sullivan, “The North American Menopause Society: From abstract to publication,” Menopause, vol. 15, no. 5, pp. 996–1001, 2008, doi: 10.1097/gme.0b013e318166f026.
  3. Ю. С. В. Сухих Г.Т., Сметник В.П., Андреева Е.Н., Балан В.Е., Гависова А.А., Григорян О.Р., Ермакова Е.И., Зайдиева Я.З., Ильина Л.М., Касян В.Н., Марченко Л.А., Подзолкова Н.М., Роговская С.И., Сметник А.А., Чернуха Г.Е., Менопаузальная гормонотерапия и сохранение здоровья женщин в зрелом возрасте. Клинические рекомендации. 2015, pp. 8–9.
  4. T. Muka et al., “Association of Vasomotor and Other Menopausal Symptoms with Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis,” PLoS One, vol. 11, p. e0157417, Jun. 2016, doi: 10.1371/journal.pone.0157417.
  5. J. L. Gordon, D. R. Rubinow, R. C. Thurston, J. Paulson, P. J. Schmidt, and S. S. Girdler, “Cardiovascular, hemodynamic, neuroendocrine, and inflammatory markers in women with and without vasomotor symptoms,” Menopause, vol. 23, no. 11, pp. 1189–1198, Nov. 2016, doi: 10.1097/GME.0000000000000689.
  6. R. C. Thurston et al., “Physiologically assessed hot flashes and endothelial function among midlife women,” Menopause, vol. 24, no. 8, pp. 886–893, Aug. 2017, doi: 10.1097/GME.0000000000000857.
  7. G. M. van Dijk et al., “The association between vasomotor symptoms and metabolic health in peri- and postmenopausal women: A systematic review,” Maturitas, vol. 80, no. 2, pp. 140–147, Feb. 2015, doi: 10.1016/j.maturitas.2014.11.016.
  8. V. M. Miller et al., “What’s in a name: are menopausal ‘hot flashes’ a symptom of menopause or a manifestation of neurovascular dysregulation?,” Menopause, vol. 25, no. 6, pp. 700–703, 2018, doi: 10.1097/gme.0000000000001065.
  9. S. V. Yureneva and V. G. Averkova, “Menopausal vasomotor symptoms: central triggers, effectors, and new possibilities of pathogenetic therapy,” Ross. Vestn. akushera-ginekologa, vol. 18, no. 5, p. 43, 2018, doi: 10.17116/rosakush20181805143.
  10. G. A. Greendale et al., “Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women’s Health Across the Nation (SWAN),” J. Bone Miner. Res., vol. 27, no. 1, pp. 111–118, Jan. 2012, doi: 10.1002/jbmr.534.
  11. F. Trémollieres, “Assessment and hormonal management of osteoporosis,” Climacteric, vol. 22, no. 2, pp. 122–126, Mar. 2019, doi: 10.1080/13697137.2018.1555582.
  12. R. Sapir-Koren and G. Livshits, “Is interaction between age-dependent decline in mechanical stimulation and osteocyte–estrogen receptor levels the culprit for postmenopausal-impaired bone formation?,” Osteoporos. Int., vol. 24, no. 6, pp. 1771–1789, 2013, doi: 10.1007/s00198-012-2208-2.
  13. “The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society,” Menopause, vol. 27, no. 9, pp. 976–992, 2020, doi: DOI: 10.1097/GME.0000000000001609.
  14. D. J. Portman, M. L. S. Gass, and on behalf of the V. A. T. C. C. Panel, “Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society,” Menopause, vol. 21, no. 10, 2014, [Online]. Available: https://journals.lww.com/menopausejournal/Fulltext/2014/10000/Genitourinary_syndrome_o
  15. D. A. J. M. Schoenaker, C. A. Jackson, J. V Rowlands, and G. D. Mishra, “Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta- analyses of studies across six continents,” Int. J. Epidemiol., vol. 43, no. 5, pp. 1542–1562, Oct. 2014, doi: 10.1093/ije/dyu094.
  16. E. W. Freeman, M. D. Sammel, and R. J. Sanders, “Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort,” Menopause, vol. 21, no. 9, pp. 924–932, Sep. 2014, doi: 10.1097/GME.0000000000000196.
  17. C. Costanian, S. Zangiabadi, S. A. Bahous, R. Deonandan, and H. Tamim, “Reviewing the evidence on vasomotor symptoms: the role of traditional and non-traditional factors,” Climacteric, vol. 23, no. 3, pp. 213–223, May 2020, doi: 10.1080/13697137.2019.1711051.
  18. N. Santoro, C. N. Epperson, and S. B. Mathews, “Menopausal Symptoms and Their Management,” Endocrinol. Metab. Clin. North Am., vol. 44, no. 3, pp. 497–515, 2015, doi: 10.1016/j.ecl.2015.05.001.
  19. G. A. Mel’Nichenko et al., “Russian federal clinical guidelines on the diagnostics, treatment, and prevention of osteoporosis,” Probl. Endokrinol. (Mosk)., vol. 63, no. 6, pp. 392– 426, 2017, doi: 10.14341/probl2017636392-426.
  20. R. J. Baber, N. Panay, and A. Fenton, “2016 IMS Recommendations on women’s midlife health and menopause hormone therapy,” Climacteric, vol. 19, no. 2, pp. 109–150, Mar. 2016, doi: 10.3109/13697137.2015.1129166.
  21. F. Palma, A. Volpe, P. Villa, and A. Cagnacci, “Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study,” Maturitas, vol. 83, pp. 40–44, Jan. 2016, doi: 10.1016/j.maturitas.2015.09.001.
  22. Y. S. V. Yureneva, E. E. I. Ermakova, and G. A. V. Glazunova, “Genitourinary syndrome of menopause in peri- and postmenopausal patients: Diagnosis and therapy (short clinical guideline),” Akush. Ginekol. (Sofiia)., vol. 5_2016, pp. 138–144, May 2016, doi: 10.18565/aig.2016.5.138-144.
  23. L. N. Wood and J. T. Anger, “Urinary incontinence in women,” BMJ Br. Med. J., vol. 349, p. g4531, Sep. 2014, doi: 10.1136/bmj.g4531.
  24. W. H. Natcher, “NIH State-of-the-Science Conference on Management of Menopause- Related Symptoms Sponsored by : National Institutes of Health,” Heal. (San Fr., vol. 3, pp. 118(suppl 2):1–172, 2005.
  25. N. E. Avis et al., “Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition,” JAMA Intern Med, vol. 175, no. 4, pp. 531–539, 2015, doi: 10.1001/jamainternmed.2014.8063.
  26. P. Monteleone, G. Mascagni, A. Giannini, A. R. Genazzani, and T. Simoncini, “Symptoms of menopause — global prevalence, physiology and implications,” Nat. Rev. Endocrinol., vol. 14, no. 4, pp. 199–215, 2018, doi: 10.1038/nrendo.2017.180.
  27. P. Briggs, “Genitourinary syndrome of menopause,” Post Reprod. Heal., vol. 26, no. 2, pp. 111–114, 2020, doi: 10.1177/2053369119884144.
  28. P. M. Maki et al., “Guidelines for the evaluation and treatment of perimenopausal depression: Summary and recommendations,” J. Women’s Heal., vol. 28, no. 2, pp. 117–134, 2019, doi: 10.1089/jwh.2018.27099.mensocrec.
  29. E. S. Mitchell and N. F. Woods, “Cognitive symptoms during the menopausal transition and early postmenopause,” Climacteric, vol. 14, no. 2, pp. 252–261, Apr. 2011, doi: 10.3109/13697137.2010.516848.
  30. H. M. Kravitz and H. Joffe, “Sleep During the Perimenopause: A SWAN Story,” Obstetrics and Gynecology Clinics of North America, vol. 38, no. 3. Elsevier, pp. 567–586, Sep. 01, 2011, doi: 10.1016/j.ogc.2011.06.002.
  31. S. M. Mallhi TH, Khan YH, Khan AH, Mahmood Q, Khalid SH, “Managing Hot Flushes in Menopausal Women: A Review,” J Coll Physicians Surg Pak., vol. Jun;28(6), pp. 460–465, 2018, doi: doi: 10.29271/jcpsp.2018.06.460.
  32. M. R. Islam, P. Gartoulla, R. J. Bell, P. Fradkin, and S. R. Davis, “Prevalence of menopausal symptoms in Asian midlife women: a systematic review,” Climacteric, vol. 18, no. 2, pp. 157–176, Mar. 2015, doi: 10.3109/13697137.2014.937689.
  33. S. Chaikittisilpa, K. Soimongkol, and U. Jaisamrarn, “Efficacy of oral estrogen plus testosterone gel to improve sexual function in postmenopausal women,” Climacteric, vol. 22, no. 5, pp. 460–465, Sep. 2019, doi: 10.1080/13697137.2019.1577378.
  34. G. Sarri, H. Pedder, S. Dias, Y. Guo, and M. A. Lumsden, “Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause,” BJOG An Int. J. Obstet. Gynaecol., vol. 124, no. 10, pp. 1514–1523, Sep. 2017, doi: https://doi.org/10.1111/1471-0528.14619.
  35. D. Harlow, P. Maki, R. W. Rebar, and E. Director, “President, International Menopause Society (South Africa),” Climacteric, vol. 15, no. 2, pp. 105–114, 2012, doi: 10.3109/13697137.2011.650656.
  36. O. Ortmann, M. Beckermann, E. Inwald, T. Strowitzki, E. Windler, and C. Tempfer, “Peri- and postmenopause—diagnosis and interventions interdisciplinary S3 guideline of the association of the scientific medical societies in Germany (AWMF 015/062): short version,” Arch. Gynecol. Obstet., vol. 302, Jul. 2020, doi: 10.1007/s00404-020-05682-4.
  37. E. Armeni et al., “Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS).,” Maturitas, vol. 89, pp. 63–72, Jul. 2016, doi: 10.1016/j.maturitas.2016.04.013.
  38. R. J. Santen et al., “Treatment of urogenital atrophy with low-dose estradiol: Preliminary results,” Menopause, vol. 9, no. 3, pp. 179–187, 2002, doi: 10.1097/00042192- 200205000-00006.
  39. “Приказ Министерства здравоохранения Российской Федерации от 20.10.2020 № 1130н "Об утверждении Порядка оказания медицинской помощи по профилю ‘акушерство и гинекология,’” 2020.
  40. “Доброкачественная дисплазия молочной железы.Клинические рекомендации.Министерство здравоохранения Россиской Федерации.,” p. 77, 2020.
  41. M. A. Lumsden, “The NICE Guideline – Menopause: diagnosis and management,” Climacteric, vol. 19, no. 5, pp. 426–429, Sep. 2016, doi: 10.1080/13697137.2016.1222483.
  42. П. С. В. и соавт. Юренева С. В. Ермакова, Ведение женщин с менопаузальными расстройствами. Учебное пособие. 2016.
  43. Е. Е. И. Юренева С.В., “Менопауза и климактерическое состояние у женщины,” Акушерство и гинекология., vol. 7, pp. 17–21, 2018.
  44. Y. S. V. Yureneva, K. V. I. Komedina, and K. S. Y. Kuznetsov, “Weight gain in perimenopausal women: methods for assessing the body composition and maintenance tactics,” Akush. Ginekol. (Sofiia)., vol. 2_2020, pp. 56–61, Mar. 2020, doi: 10.18565/aig.2020.2.56-61.
  45. C. A. Stuenkel et al., “Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline,” J. Clin. Endocrinol. Metab., vol. 100, no. 11, pp. 3975–4011, Nov. 2015, doi: 10.1210/jc.2015-2236.
  46. National Collaborating Centre for Women’s and Children’s Health (UK). Menopause: Full Guideline. London: National Institute for Health and Care Excellence. London, 2015.
  47. M. G. Munro, H. O. D. Critchley, and I. S. Fraser, “The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions.,” Int. J. Gynaecol. Obstet. Off. organ Int. Fed. Gynaecol. Obstet., vol. 143, no. 3, pp. 393–408, Dec. 2018, doi: 10.1002/ijgo.12666.
  48. Menopause Practice (5th Edition) : A Clinician’s Guide.The North American Menopause Society. 2014.
  49. E. A. Pigarova et al., “Russian Association of Endocrinologists recommendations for diagnosis, treatment and prevention of Vitamin D deficiency in adults,” Probl. Endokrinol. (Mosk)., vol. 62, no. 4, pp. 60–84, 2016, doi: 10.14341/probl201662460-84.
  50. Fahey M. T., Irwig L., Macaskill P. Meta-analysis of Pap test accuracy //American journal of epidemiology. – 1995. – Т. 141. – №. 7. – С. 680-689. .
  51. Meggiolaro A., Unim B., Semyonov L., Miccoli S., Maffongelli E., La Torre G. The role of Pap test screening against cervical cancer: a systematic review and meta-analysis. Clin Ter. 167(4):124–39. .
  52. Wang J. Analysis of the application values of different combination schemes of liquid-based cytology and high-risk human papilloma virus test in the screening of high-grade cervical lesions //Brazilian Journal of Medical and Biological Research. – 2019. .
  53. J. A. Kanis, C. Cooper, & R. Rizzoli, and J.-Y. Reginster, “European guidance for the diagnosis and management of osteoporosis in postmenopausal women,” doi: 10.1007/s00198-018-4704-5.
  54. W. D. Leslie, S. Morin, L. M. Lix, and H. Johansson, “Fracture risk assessment without bone density measurement in routine clinical practice,” 2011, doi: 10.1007/s00198-011- 1747-2.
  55. W. D. Leslie et al., “High fracture probability with FRAX® usually indicates densitometric osteoporosis: implications for clinical practice,” Osteoporos. Int., vol. 23, no. 1, pp. 391–397, 2012, doi: 10.1007/s00198-011-1592-3.
  56. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization, Geneva. World Health Organ Tech Rep Ser. 1994;843:1-129. .
  57. Nelson HD, Haney EM. Screening for Osteoporosis: Systematic Review to Update the 2002 US Preventive Services Task Force Recommendation. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 Jul. Report No.: 10-05145-EF-1. .
  58. N. Panay et al., “Premature ovarian insufficiency: an International Menopause Society White Paper.,” Climacteric, vol. 23, no. 5, pp. 426–446, Oct. 2020, doi: 10.1080/13697137.2020.1804547.
  59. X. Xu, M. Jones, and G. D. Mishra, “Age at natural menopause and development of chronic conditions and multimorbidity: results from an Australian prospective cohort.,” Hum. Reprod., vol. 35, no. 1, pp. 203–211, Jan. 2020, doi: 10.1093/humrep/dez259.
  60. “International Society for Clinical Densitometry position statement 2019.” https://www.iscd.org/official-positions/2019-iscd-official-positions-adult.
  61. L. Shepstone et al., “Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial.,” Lancet (London, England), vol. 391, no. 10122, pp. 741–747, Feb. 2018, doi: 10.1016/S0140-6736(17)32640-5.
  62. Jiang X, Gruner M. Diagnostic accuracy of FRAX in predicting the 10-year risk of osteoporotic fractures using the USA treatment thresholds: A systematic review and meta- analysis. Bone. 2017 Jun;99:20-25. .
  63. T. B. Bevers et al., “Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.,” J. Natl. Compr. Canc. Netw., vol. 16, no. 11, pp. 1362–1389, Nov. 2018, doi: 10.6004/jnccn.2018.0083.
  64. R. H. Cobin and N. F. Goodman, “American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Menopause–2017 Update,” Endocr. Pract., vol. 23, no. 7, pp. 869–881, Jul. 2017, doi: 10.4158/EP171828.PS.
  65. H. Okano et al., “Japan Society of Obstetrics and Gynecology and Japan Society for Menopause and Women’s Health 2017 guidelines for hormone replacement therapy,” J. Obstet. Gynaecol. Res., vol. 44, no. 8, pp. 1355–1368, Aug. 2018, doi: https://doi.org/10.1111/jog.13684.
  66. G. Casanova, R. Bossardi Ramos, P. Ziegelmann, and P. M. Spritzer, “Effects of Low- Dose Versus Placebo or Conventional-Dose Postmenopausal Hormone Therapy on Variables Related to Cardiovascular Risk: A Systematic Review and Meta-Analyses of Randomized Clinical Trials,” J. Clin. Endocrinol. Metab., vol. 100, no. 3, pp. 1028–1037, Mar. 2015, doi: 10.1210/jc.2014-3301.
  67. S. R. Salpeter, J. M. E. Walsh, T. M. Ormiston, E. Greyber, N. S. Buckley, and E. E. Salpeter, “Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women.,” Diabetes. Obes. Metab., vol. 8, no. 5, pp. 538–554, Sep. 2006, doi: 10.1111/j.1463-1326.2005.00545.x.
  68. M. Canonico, G. Plu-Bureau, G. D. O. Lowe, and P.-Y. Scarabin, “Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis.,” BMJ, vol. 336, no. 7655, pp. 1227–1231, May 2008, doi: 10.1136/bmj.39555.441944.BE.
  69. Menopause Practice: A Clinician’s Guide 5-th Edition. The American Menopause Society. 2014.
  70. “The 2017 hormone therapy position statement of The North American Menopause Society.,” Menopause, vol. 24, no. 7, pp. 728–753, Jul. 2017, doi: 10.1097/GME.0000000000000921.
  71. L. Webber et al., “ESHRE Guideline: management of women with premature ovarian insufficiency.,” Hum. Reprod., vol. 31, no. 5, pp. 926–937, May 2016, doi: 10.1093/humrep/dew027.
  72. C. Biehl, O. Plotsker, and S. Mirkin, “A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause.,” Menopause, vol. 26, no. 4, pp. 431–453, Apr. 2019, doi: 10.1097/GME.0000000000001221.
  73. Marjoribanks J. et al. Long term hormone therapy for perimenopausal and postmenopausal women //Cochrane Database of Systematic Reviews. – 2012. – №. 7. .
  74. B. Ettinger et al., “Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density : A Randomized Clinical Trial,” pp. 443–451, doi: 10.1097/01.AOG.0000137833.43248.79.
  75. J. E. Rossouw et al., “Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial.,” JAMA, vol. 288, no. 3, pp. 321–333, Jul. 2002, doi: 10.1001/jama.288.3.321.
  76. N. Burgos et al., “Estrogen-based hormone therapy in women with primary ovarian insufficiency: a systematic review.,” Endocrine, vol. 58, no. 3, pp. 413–425, Dec. 2017, doi: 10.1007/s12020-017-1435-x.
  77. S. Tsiligiannis, N. Panay, and J. C. Stevenson, “Premature Ovarian Insufficiency and Long-Term Health Consequences.,” Curr. Vasc. Pharmacol., vol. 17, no. 6, pp. 604–609, 2019, doi: 10.2174/1570161117666190122101611.
  78. S. Gordhandas, B. M. Norquist, K. P. Pennington, R. L. Yung, M. B. Laya, and E. M. Swisher, “Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.,” Gynecol. Oncol., vol. 153, no. 1, pp. 192–200, Apr. 2019, doi: 10.1016/j.ygyno.2018.12.014.
  79. M. Ulin, M. Ali, Z. T. Chaudhry, A. Al-Hendy, and Q. Yang, “Uterine fibroids in menopause and perimenopause,” Menopause, vol. 27, no. 2, pp. 238–242, 2020, doi: 10.1097/GME.0000000000001438.
  80. C. Oliver-Williams et al., “The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review.,” Hum. Reprod. Update, vol. 25, no. 2, pp. 257–271, Mar. 2019, doi: 10.1093/humupd/dmy039.
  81. N. Biglia, A. Gadducci, R. Ponzone, R. Roagna, and P. Sismondi, “Hormone replacement therapy in cancer survivors.,” Maturitas, vol. 48, no. 4, pp. 333–346, Aug. 2004, doi: 10.1016/j.maturitas.2003.09.031.
  82. S. Kim, Y. Ko, H. J. Lee, and J.-E. Lim, “Menopausal hormone therapy and the risk of breast cancer by histological type and race: a meta-analysis of randomized controlled trials and cohort studies.,” Breast Cancer Res. Treat., vol. 170, no. 3, pp. 667–675, Aug. 2018, doi: 10.1007/s10549-018-4782-2.
  83. M. R. Rizzo, S. Leo, P. De Franciscis, N. Colacurci, and G. Paolisso, “Short-term effects of low-dose estrogen/drospirenone vs low-dose estrogen/dydrogesterone on glycemic fluctuations in postmenopausal women with metabolic syndrome,” Age (Omaha)., vol. 36, no. 1, pp. 265–274, 2014, doi: 10.1007/s11357-013-9554-7.
  84. W. B. White, V. Hanes, M. Mallareddy, and V. Chauhan, “Effects of the hormone therapy, drospirenone and 17-beta estradiol, on early morning blood pressure in postmenopausal women with hypertension.,” J. Am. Soc. Hypertens., vol. 2, no. 1, pp. 20–27, 2008, doi: 10.1016/j.jash.2007.08.004.
  85. R. Kagan, G. Constantine, A. M. Kaunitz, B. Bernick, and S. Mirkin, “Improvement in sleep outcomes with a 17 b -estradiol–progesterone oral capsule (TX-001HR) for postmenopausal women,” vol. 26, no. 6, pp. 622–628, 2019, doi: 10.1097/GME.0000000000001278.
  86. G. Formoso et al., “Short-term and long-term effects of tibolone in postmenopausal women.,” Cochrane database Syst. Rev., vol. 10, no. 10, p. CD008536, Oct. 2016, doi: 10.1002/14651858.CD008536.pub3.
  87. S. Tsiligiannis, B. C. Wick-Urban, J. van der Stam, and J. C. Stevenson, “Efficacy and safety of a low-dose continuous combined hormone replacement therapy with 0.5 mg 17β- estradiol and 2.5 mg dydrogesterone in subgroups of postmenopausal women with vasomotor symptoms.,” Maturitas, vol. 139, pp. 20–26, Sep. 2020, doi: 10.1016/j.maturitas.2020.05.002.
  88. D. F. Archer, J. H. Pickar, D. C. MacAllister, and M. P. Warren, “Transdermal estradiol gel for the treatment of symptomatic postmenopausal women,” Menopause, vol. 19, no. 6, pp. 622–629, 2012, doi: 10.1097/gme.0b013e31823b8867.
  89. Y. Vinogradova, C. Coupland, and J. Hippisley-Cox, “Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.,” BMJ, vol. 364, p. k4810, Jan. 2019, doi: 10.1136/bmj.k4810.
  90. M. Canonico et al., “Postmenopausal hormone therapy and risk of stroke: Impact of the route of estrogen administration and type of progestogen,” Stroke, vol. 47, no. 7, pp. 1734– 1741, 2016, doi: 10.1161/STROKEAHA.116.013052.
  91. M. Canonico, “Hormone therapy and risk of venous thromboembolism among postmenopausal women.,” Maturitas, vol. 82, no. 3, pp. 304–307, Nov. 2015, doi: 10.1016/j.maturitas.2015.06.040.
  92. A. Fournier, F. Berrino, and F. Clavel-Chapelon, “Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.,” Breast Cancer Res. Treat., vol. 107, no. 1, pp. 103–111, Jan. 2008, doi: 10.1007/s10549- 007-9523-x.
  93. Y. Vinogradova, C. Coupland, and J. Hippisley-Cox, “Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases.,” BMJ, vol. 371, p. m3873, Oct. 2020, doi: 10.1136/bmj.m3873.
  94. H. Lyytinen, E. Pukkala, and O. Ylikorkala, “Breast cancer risk in postmenopausal women using estradiol-progestogen therapy.,” Obstet. Gynecol., vol. 113, no. 1, pp. 65–73, Jan. 2009, doi: 10.1097/AOG.0b013e31818e8cd6.
  95. J. Hugon-Rodin, S. Perol, and G. Plu-Bureau, “[Menopause and risk of thromboembolic events. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines].,” Gynecologie, obstetrique, fertilite & senologie, vol. 49, no. 5. France, pp. 455–461, May 2021, doi: 10.1016/j.gofs.2021.03.018.
  96. E. Moro et al., “The impact of hormonal replacement treatment in postmenopausal women with uterine fibroids: A state-of-the-art review of the literature,” Med., vol. 55, no. 9, 2019, doi: 10.3390/medicina55090549.
  97. V. Beral, K. Gaitskell, C. Hermon, K. Moser, G. Reeves, and R. Peto, “Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies.,” Lancet (London, England), vol. 385, no. 9980, pp. 1835–1842, May 2015, doi: 10.1016/S0140-6736(14)61687-1.
  98. C. Castelo-Branco et al., “Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: benefits to bone and analysis of factors associated with discontinuation,” Menopause, vol. 6, no. 4, pp. 307–311, 1999, doi: 10.1097/00042192- 199906040-00006.
  99. С. В. Ю. Совместная позиция экспертов РОАГ, РАМ, АГЭ, РАОП / под ред. В.Н. Серова, “Алгоритмы применения менопаузальной гормональной терапии у женщин в период пери- и постменопаузы.,” Акушерство и гинекология., vol. 3: 210-221, 2021, doi: https://dx.doi.org/10.18565/aig.2021.3.210-221.
  100. P. Stute, J. Neulen, and L. Wildt, “The impact of micronized progesterone on the endometrium: a systematic review.,” Climacteric, vol. 19, no. 4, pp. 316–328, Aug. 2016, doi: 10.1080/13697137.2016.1187123.
  101. M. Bińkowska and J. Woroń, “Progestogens in menopausal hormone therapy.,” Prz. menopauzalny = Menopause Rev., vol. 14, no. 2, pp. 134–143, Jun. 2015, doi: 10.5114/pm.2015.52154.
  102. D. Sanchez-Rodriguez et al., “The Belgian Bone Club 2020 guidelines for the management of osteoporosis in postmenopausal women,” Maturitas, vol. 139, no. May, pp. 69–89, 2020, doi: 10.1016/j.maturitas.2020.05.006.
  103. “Committee Opinion No. 698: Hormone Therapy in Primary Ovarian Insufficiency.,” Obstet. Gynecol., vol. 129, no. 5, pp. e134–e141, May 2017, doi: 10.1097/AOG.0000000000002044.
  104. B. Cartwright, J. Robinson, P. T. Seed, I. Fogelman, and J. Rymer, “Hormone Replacement Therapy Versus the Combined Oral Contraceptive Pill in Premature Ovarian Failure: A Randomized Controlled Trial of the Effects on Bone Mineral Density,” J. Clin. Endocrinol. Metab., vol. 101, no. 9, pp. 3497–3505, Sep. 2016, doi: 10.1210/jc.2015-4063.
  105. J. P. Langrish et al., “Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure.,” Hypertens. (Dallas, Tex. 1979), vol. 53, no. 5, pp. 805–811, May 2009, doi: 10.1161/HYPERTENSIONAHA.108.126516.
  106. T. R. Rebbeck et al., “Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.,” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 23, no. 31, pp. 7804–7810, Nov. 2005, doi: 10.1200/JCO.2004.00.8151.
  107. A. R. Genazzani, T. Schmelter, M. Schaefers, C. Gerlinger, and K. Gude, “One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women.,” Climacteric, vol. 16, no. 4, pp. 490–498, Aug. 2013, doi: 10.3109/13697137.2013.783797.
  108. E. Hirvonen, B. Cacciatore, T. Wahlström, H. Rita, and G. Wilén-Rosenqvist, “Effects of transdermal oestrogen therapy in postmenopausal women: a comparative study of an oestradiol gel and an oestradiol delivering patch.,” Br. J. Obstet. Gynaecol., vol. 104 Suppl, pp. 26–31, Nov. 1997, doi: 10.1111/j.1471-0528.1997.tb11564.x.
  109. J. C. Stevenson, G. Durand, E. Kahler, and T. Pertyński, “Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study.,” Maturitas, vol. 67, no. 3, pp. 227–232, Nov. 2010, doi: 10.1016/j.maturitas.2010.07.002.
  110. U. Jaisamrarn, S. Triratanachat, S. Chaikittisilpa, P. Grob, V. Prasauskas, and N. Taechakraichana, “Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy,” Climacteric, vol. 16, no. 3, pp. 347–355, 2013, doi: 10.3109/13697137.2013.769097.
  111. Y. S. V. Yureneva, G. A. V. Glazunova, E. E. G. Eprikyan, D. A. E. Donnikov A, and E. L. S. Ezhova, “Therapy for vulvovaginal atrophy in postmenopausal women: Clinical and pathogenetic aspects,” Akush. Ginekol. (Sofiia)., vol. 6_2017, pp. 143–150, Jul. 2017, doi: 10.18565/aig.2017.6.143-50.
  112. C. Perrotta, M. Aznar, R. Mejia, X. Albert, and C. W. Ng, “Oestrogens for preventing recurrent urinary tract infection in postmenopausal women.,” Cochrane database Syst. Rev., no. 2, p. CD005131, Apr. 2008, doi: 10.1002/14651858.CD005131.pub2.
  113. L. Cardozo, G. Bachmann, D. McClish, D. Fonda, and L. Birgerson, “Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee.,” Obstet. Gynecol., vol. 92, no. 4 Pt 2, pp. 722–727, Oct. 1998, doi: 10.1016/s0029-7844(98)00175-6.
  114. C. Rueda, A. M. Osorio, A. C. Avellaneda, C. E. Pinzón, and O. I. Restrepo, “The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review.,” Climacteric, vol. 20, no. 4, pp. 321–330, Aug. 2017, doi: 10.1080/13697137.2017.1329291.
  115. S. Weidlinger, C. Schmutz, H. Janka, C. Gruetter, and P. Stute, “Sustainability of vaginal estrogens for genitourinary syndrome of menopause - a systematic review.,” Climacteric, pp. 1–9, Mar. 2021, doi: 10.1080/13697137.2021.1891218.
  116. A. L. Hirschberg et al., “Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide,” Maturitas, no. April, Apr. 2021, doi: 10.1016/j.maturitas.2021.04.005.
  117. A. O. Mueck, X. Ruan, V. Prasauskas, P. Grob, and O. Ortmann, “Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review.,” Climacteric, vol. 21, no. 2, pp. 140–147, Apr. 2018, doi: 10.1080/13697137.2017.1421923.
  118. S. A. A. Orazov М.R. Radzinsky V.E., Balan V.E., Khamoshina М.В., Toktar L.R., “Combination Local Therapy of Genitourinary Menopausal Syndrome Symptoms,” World J. Gynecol. Womens Heal., vol. 3, no. 5, pp. 3–9, 2020, doi: 10.33552/wjgwh.2020.03.000575.
  119. D. Y. Pushkar and M. Y. Gvozdev, “Dynamics of symptoms of genitourinary menopausal syndrome and the frequency of recurrence of lower urinary tract infection in women in periand postmenopausal patients with combined therapy with Trioginal®,” Gynecology, vol. 20, no. 6, pp. 67–72, 2018, doi: 10.26442/20795696.2018.6.180119.
  120. A. V. K. Kuzmenko, V. V. K. Kuzmenko, and T. A. G. Gyaurgiev, “Experience of application of hormonal and probiotic therapy in the complex treatment of women in peri- and postmenopausal with chronic recurrent bacterial cystitis in the background of vulvovaginal atrophy,” Urologiia, vol. 3_2019, pp. 66–71, Jul. 2019, doi: 10.18565/urology.2019.3.66-71.
  121. R. M. Islam, R. J. Bell, S. Green, M. J. Page, and S. R. Davis, “Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data.,” lancet. Diabetes Endocrinol., vol. 7, no. 10, pp. 754–766, Oct. 2019, doi: 10.1016/S2213-8587(19)30189-5.
  122. The North American Menopause Society, “Statement on Continuing Use of Systemic Hormone Therapy After Age 65,” vol. 22, no. 141, p. 2015, 2015.
  123. “Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society.,” Menopause, vol. 22, no. 11, pp. 1154–1155, Nov. 2015, doi: 10.1097/GME.0000000000000546.
  124. P. Stute et al., “A model of care for healthy menopause and ageing: EMAS position statement,” Maturitas, vol. 92, pp. 1–6, 2016, doi: 10.1016/j.maturitas.2016.06.018.
  125. G. Mintziori et al., “EMAS position statement: Non-hormonal management of menopausal vasomotor symptoms.,” Maturitas, vol. 81, no. 3, pp. 410–413, Jul. 2015, doi: 10.1016/j.maturitas.2015.04.009.
  126. T. R. Moore, R. B. Franks, and C. Fox, “Review of Efficacy of Complementary and Alternative Medicine Treatments for Menopausal Symptoms.,” J. Midwifery Womens. Health, vol. 62, no. 3, pp. 286–297, May 2017, doi: 10.1111/jmwh.12628.
  127. and L. H. HD Nelson, KK Vesco, E Haney, R Fu, A Nedrow, J Miller, C Nicolaidis, M Walker, “Nonhormonal therapies for menopausal hot flashes: systematic review and meta- analysis,” Database Abstr. Rev. Eff. Qual. Rev. [Internet]., 2006.
  128. A. Bardia, P. Novotny, J. Sloan, D. Barton, and C. Loprinzi, “Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis,” Menopause, vol. 16, no. 3, pp. 477–483, 2009, doi: 10.1097/gme.0b013e31818c91ca.
  129. M. Rees et al., “European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis.,” Maturitas, vol. 134, pp. 56–61, Apr. 2020, doi: 10.1016/j.maturitas.2020.01.005.
  130. C. L. Loprinzi et al., “Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial.,” Lancet (London, England), vol. 356, no. 9247, pp. 2059–2063, Dec. 2000, doi: 10.1016/S0140-6736(00)03403-6.
  131. C. H. Kroenke et al., “Effects of a dietary intervention and weight change on vasomotor symptoms in the Women’s Health Initiative Candyce,” Menopause, vol. 19, no. 9, pp. 980–988, 2013, doi: 10.1097/gme.0b013e31824f606e.Effects.
  132. S. Norton, J. Chilcot, and M. S. Hunter, “Cognitive-behavior therapy for menopausal symptoms (hot flushes and night sweats): moderators and mediators of treatment effects.,” Menopause, vol. 21, no. 6, pp. 574–578, Jun. 2014, doi: 10.1097/GME.0000000000000095.
  133. E. Mann, M. Smith, J. Hellier, and M. S. Hunter, “A randomised controlled trial of a cognitive behavioural intervention for women who have menopausal symptoms following breast cancer treatment (MENOS 1): trial protocol.,” BMC Cancer, vol. 11, p. 44, Jan. 2011, doi: 10.1186/1471-2407-11-44.
  134. B. Ayers, M. Smith, J. Hellier, E. Mann, and M. S. Hunter, “Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial.,” Menopause, vol. 19, no. 7, pp. 749– 759, Jul. 2012, doi: 10.1097/gme.0b013e31823fe835.
  135. Q. Zhang, F. Li, H. Zhang, X. Yu, and Y. Cong, “Effects of nurse-led home-based exercise & cognitive behavioral therapy on reducing cancer-related fatigue in patients with ovarian cancer during and after chemotherapy: A randomized controlled trial.,” Int. J. Nurs. Stud., vol. 78, pp. 52–60, Feb. 2018, doi: 10.1016/j.ijnurstu.2017.08.010.
  136. G. R. Elkins, W. I. Fisher, A. K. Johnson, J. S. Carpenter, and T. Z. Keith, “Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial.,” Menopause, vol. 20, no. 3, pp. 291–298, Mar. 2013, doi: 10.1097/gme.0b013e31826ce3ed.
  137. H.-Y. Chiu, C.-H. Pan, Y.-K. Shyu, B.-C. Han, and P.-S. Tsai, “Effects of acupuncture on menopause-related symptoms and quality of life in women in natural menopause: a meta- analysis of randomized controlled trials.,” Menopause, vol. 22, no. 2, pp. 234–244, Feb. 2015, doi: 10.1097/GME.0000000000000260.
  138. П. А. С. Ярмолинская М.И., Татарова Н.А., Касян В.Н., “Эффективность негормональной терапии в лечении женщин с климактерическим синдромом,” Российский вестник акушера-гинеколога., vol. 21, no. 2, pp. 88–89, 2021.
  139. S. V. Yureneva, T. Y. Ivanets, E. I. Ermakova, and V. G. Averkova, “The results of an open-label comparative randomized controlled clinical trial of the use of combined treatment including Pineamin in postmenopausal women,” Ross. Vestn. akushera-ginekologa, vol. 20, no. 2, p. 86, 2020, doi: 10.17116/rosakush20202002186.
  140. M. S. Lee, J.-I. Kim, J. Y. Ha, K. Boddy, and E. Ernst, “Yoga for menopausal symptoms: a systematic review.,” Menopause, vol. 16, no. 3, pp. 602–608, 2009, doi: 10.1097/gme.0b013e31818ffe39.
  141. K. M. Newton et al., “Efficacy of yoga for vasomotor symptoms: a randomized controlled trial.,” Menopause, vol. 21, no. 4, pp. 339–346, Apr. 2014, doi: 10.1097/GME.0b013e31829e4baa.
  142. D. Anderson, C. Seib, and L. Rasmussen, “Can physical activity prevent physical and cognitive decline in postmenopausal women?: A systematic review of the literature,” Maturitas, vol. 79, no. 1, pp. 14–33, Sep. 2014, doi: 10.1016/j.maturitas.2014.06.010.
  143. A. Daley, H. Stokes-Lampard, A. Thomas, and C. MacArthur, “Exercise for vasomotor menopausal symptoms.,” Cochrane database Syst. Rev., no. 11, p. CD006108, Nov. 2014, doi: 10.1002/14651858.CD006108.pub4.
  144. G. Elkins et al., “Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors.,” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 26, no. 31, pp. 5022–5026, Nov. 2008, doi: 10.1200/JCO.2008.16.6389.
  145. C. L. Loprinzi et al., “Newer Antidepressants and Gabapentin for Hot Flashes: An Individual Patient Pooled Analysis,” J. Clin. Oncol., vol. 27, no. 17, pp. 2831–2837, Mar. 2009, doi: 10.1200/JCO.2008.19.6253.
  146. A. E. Kalay, B. Demir, A. Haberal, M. Kalay, and O. Kandemir, “Efficacy of citalopram on climacteric symptoms.,” Menopause, vol. 14, no. 2, pp. 223–229, 2007, doi: 10.1097/01.gme.0000243571.55699.4a.
  147. K. E. Ensrud et al., “Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial.,” Menopause, vol. 19, no. 8, pp. 848–855, Aug. 2012, doi: 10.1097/gme.0b013e3182476099.
  148. J. A. Simon et al., “Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials.,” Menopause, vol. 20, no. 10, pp. 1027–1035, Oct. 2013, doi: 10.1097/GME.0b013e3182a66aa7.
  149. H. Joffe et al., “Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.,” JAMA Intern. Med., vol. 174, no. 7, pp. 1058–1066, Jul. 2014, doi: 10.1001/jamainternmed.2014.1891.
  150. T. Shams et al., “SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials.,” J. Gen. Intern. Med., vol. 29, no. 1, pp. 204–213, Jan. 2014, doi: 10.1007/s11606-013-2535-9.
  151. Z. Sun, Y. Hao, and M. Zhang, “Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials.,” Gynecol. Obstet. Invest., vol. 75, no. 4, pp. 255–262, 2013, doi: 10.1159/000348564.
  152. D. Grady, B. Cohen, J. Tice, M. Kristof, A. Olyaie, and G. F. Sawaya, “Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial.,” Obstet. Gynecol., vol. 109, no. 4, pp. 823–830, Apr. 2007, doi: 10.1097/01.AOG.0000258278.73505.fa.
  153. E. W. Freeman et al., “Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.,” JAMA, vol. 305, no. 3, pp. 267–274, Jan. 2011, doi: 10.1001/jama.2010.2016.
  154. V. Stearns et al., “Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial.,” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 23, no. 28, pp. 6919–6930, Oct. 2005, doi: 10.1200/JCO.2005.10.081.
  155. J. S. Carpenter et al., “Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer.,” Oncologist, vol. 12, no. 1, pp. 124–135, Jan. 2007, doi: 10.1634/theoncologist.12-1-124.
  156. L. Speroff, M. Gass, G. Constantine, and S. Olivier, “Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.,” Obstet. Gynecol., vol. 111, no. 1, pp. 77–87, Jan. 2008, doi: 10.1097/01.AOG.0000297371.89129.b3.
  157. Y.-S. Cheng, C.-K. Sun, P.-Y. Yeh, M.-K. Wu, K.-C. Hung, and H.-J. Chiu, “Serotonergic antidepressants for sleep disturbances in perimenopausal and postmenopausal women: a systematic review and meta-analysis.,” Menopause, vol. 28, no. 2, pp. 207–216, Sep. 2020, doi: 10.1097/GME.0000000000001647.
  158. O. V. Shabalova, S. V. Yureneva, S. V. Khokhlova, Z. R. Gardanova, and E. I. Ermakova, “Managing menopausal symptoms in patients with hormone receptor-positive gynecologic cancers,” J. Mod. Oncol., vol. 22, no. 3, pp. 154–159, Nov. 2020, doi: 10.26442/18151434.2020.3.200104.
  159. Suvanto-Luukkonen E. et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study //Menopause. – 2005. – Т. 12. – №. 1. – С. 18-26.
  160. В. Н. Прилепская et al., “Новое В Профилактике И Терапии Климактерического Синдрома,” Гинекология, vol. 18, no. 1, pp. 1–8, 2016.
  161. C. Castelo-Branco et al., “Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms - an update on the evidence.,” Climacteric, vol. 24, no. 2, pp. 109–119, Apr. 2021, doi: 10.1080/13697137.2020.1820477.
  162. Б. В. Е. Рафаэлян И.В. and Ковалева Л.А., “Эффективность и безопасность применения экстракта цимицифуги рацемозы в терапии климактерического синдрома в течение года (результаты собственного исследования),” Медицинский совет, vol. 7, pp. 54–57, 2014, doi: https://doi.org/10.21518/2079-701X-2014-7-54-57.
  163. Delaroix P., “Abufen 400 mg. Double blind plasebocontroled trial. Laboratories Adrian- Marinier.,” data file, 1978.
  164. Roueche J. et al., “Clinical trial report of double bind study of beta-alanin versus placebo in the treatment of hot flushes caused by climacteric syndrome and by the menopause. Laboratories DOMS-Adrian.,” data file, 1991.
  165. E. Andreeva and B. Tkeshelashvili, “Women dealing with hot flushes: The role of β- alanine,” Eur. Rev. Med. Pharmacol. Sci., vol. 24, no. 9, pp. 5148–5154, 2020, doi: 10.26355/eurrev_202005_21209.
  166. К. И. А. Овсянникова Т.В., Макаров И.О., “Клиническая эффективность негормональных методов терапии у женщин в перименопаузе.,” Акушерство, Гинекология и Репродукция., vol. 7(3), pp. 26–29, 2013.
  167. S. S. Faubion, R. Sood, and E. Kapoor, “Genitourinary Syndrome of Menopause: Management Strategies for the Clinician.,” Mayo Clin. Proc., vol. 92, no. 12, pp. 1842–1849, Dec. 2017, doi: 10.1016/j.mayocp.2017.08.019.
  168. R. Kagan, S. Kellogg-Spadt, and S. J. Parish, “Practical Treatment Considerations in the Management of Genitourinary Syndrome of Menopause.,” Drugs Aging, vol. 36, no. 10, pp. 897–908, Oct. 2019, doi: 10.1007/s40266-019-00700-w.
  169. S. S. Faubion et al., “Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health,” vol. 25, no. 6, pp. 596–608, 2018, doi: 10.1097/GME.0000000000001121.
  170. M. Hickey, J. L. Marino, S. Braat, and S. Wong, “A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer.,” Breast Cancer Res. Treat., vol. 158, no. 1, pp. 79–90, Jul. 2016, doi: 10.1007/s10549- 016-3865-1.
  171. Pitsouni, E., Grigoriadis (2018). Efficacy of vaginal therapies alternative to vaginal estrogens on sexual function and orgasm of menopausal women: A systematic review and meta- analysis of randomized controlled trials. European Journal of Obstetrics & Gyn. .
  172. V. Colpani et al., “Lifestyle factors, cardiovascular disease and all-cause mortality in middle-aged and elderly women: a systematic review and meta-analysis.,” Eur. J. Epidemiol., vol. 33, no. 9, pp. 831–845, Sep. 2018, doi: 10.1007/s10654-018-0374-z.
  173. E. Kapoor, M. L. Collazo-Clavell, and S. S. Faubion, “Weight Gain in Women at Midlife: A Concise Review of the Pathophysiology and Strategies for Management.,” Mayo Clin. Proc., vol. 92, no. 10, pp. 1552–1558, Oct. 2017, doi: 10.1016/j.mayocp.2017.08.004.
  174. I. I. Dedov et al., “Interdisciplinary Clinical Practice Guidelines ‘Management of Obesity and Its Comorbidities,’” Obe. Metab., vol. 18, no. 1, pp. 5–99, 2021, doi: 10.14341/omet12714.
  175. S. Khandelwal, “Obesity in midlife: lifestyle and dietary strategies.,” Climacteric, vol. 23, no. 2, pp. 140–147, Apr. 2020, doi: 10.1080/13697137.2019.1660638.
  176. I. Lambrinoudaki et al., “EMAS position statement: Diet and health in midlife and beyond.,” Maturitas, vol. 74, no. 1, pp. 99–104, Jan. 2013, doi: 10.1016/j.maturitas.2012.10.019.
  177. J. T. Chang, G. M. Anic, B. L. Rostron, M. Tanwar, and C. M. Chang, “Cigarette Smoking Reduction and Health Risks: A Systematic Review and Meta-analysis.,” Nicotine Tob. Res. Off. J. Soc. Res. Nicotine Tob., vol. 23, no. 4, pp. 635–642, Mar. 2021, doi: 10.1093/ntr/ntaa156.
  178. T. Ngandu et al., “A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.,” Lancet (London, England), vol. 385, no. 9984, pp. 2255–2263, Jun. 2015, doi: 10.1016/S0140-6736(15)60461-5.
  179. M. Kivipelto, F. Mangialasche, and T. Ngandu, “Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease.,” Nat. Rev. Neurol., vol. 14, no. 11, pp. 653–666, Nov. 2018, doi: 10.1038/s41582-018-0070-3.
  180. R. Nelson, “HRT Update Regarding Breast Cancer Risk Advised in EU,” Medscape Medical News, 2020. https://www.medscape.com/viewarticle/930707.
  181. C. G. on H. F. in B. Cancer, “Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence,” Lancet (London, England), vol. 394, no. 10204, pp. 1159–1168, Sep. 2019, doi: 10.1016/S0140-6736(19)31709-X.
  182. E. Cordina-Duverger et al., “Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.,” PLoS One, vol. 8, no. 11, p. e78016, 2013, doi: 10.1371/journal.pone.0078016.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*